Clinical implementation of next-generation sequencing testing and genomically-matched therapy: a real-world data in a tertiary hospital
Abstract Next-generation sequencing (NGS) cancer profiling has gained traction in routine clinical practice in South Korea. Here, we evaluated the use of NGS testing and genomically-matched therapies for patients with advanced solid tumors in a real-world clinical practice. We analyzed results from...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-01-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-024-84909-9 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832594668040224768 |
|---|---|
| author | Jin Won Kim Hee Young Na Sejoon Lee Ji-Won Kim Koung Jin Suh Se Hyun Kim Yu Jung Kim Keun-Wook Lee Jong Seok Lee Jaihwan Kim Jin-Hyeok Hwang Kihwan Hwang Chae-Yong Kim Yong Beom Kim Soomin Ahn Kyu Sang Lee Hyojin Kim Hye Seung Lee So Yeon Park Gheeyoung Choe Jee Hyun Kim Jin-Haeng Chung |
| author_facet | Jin Won Kim Hee Young Na Sejoon Lee Ji-Won Kim Koung Jin Suh Se Hyun Kim Yu Jung Kim Keun-Wook Lee Jong Seok Lee Jaihwan Kim Jin-Hyeok Hwang Kihwan Hwang Chae-Yong Kim Yong Beom Kim Soomin Ahn Kyu Sang Lee Hyojin Kim Hye Seung Lee So Yeon Park Gheeyoung Choe Jee Hyun Kim Jin-Haeng Chung |
| author_sort | Jin Won Kim |
| collection | DOAJ |
| description | Abstract Next-generation sequencing (NGS) cancer profiling has gained traction in routine clinical practice in South Korea. Here, we evaluated the use of NGS testing and genomically-matched therapies for patients with advanced solid tumors in a real-world clinical practice. We analyzed results from NGS cancer panel tests (SNUBH pan-cancer version 2) ordered from June 2019 to June 2020. Genomically-matched treatment was determined based on the novel information obtained from NGS testing, while results from conventional molecular tests were excluded. A total of 990 patients were included in the analysis (median age: 62, Stage IV: 82.5%). Using the Association for Molecular Pathology genetic variant classification system, we found that 257 (26.0%) patients harbored tier I variants, and 859 (86.8%) patients carried tier II variants. Among the tier I cases, the most frequently altered genes we detected were KRAS (106 patients, 10.7%), followed by EGFR (27 patients, 2.7%) and BRAF (17 patients, 1.7%). Of patients with tier I variants, 13.7% received NGS-based therapy as follows: Thyroid cancer (2/7, 28.6%), skin cancer (2/8, 25.0%), gynecologic cancer (7/65, 10.8%), and lung cancer (12/112, 10.7%). Of 32 patients with measurable lesions who received NGS-based therapy, 12 (37.5%) achieved a partial response, and 11 (34.4%) achieved stable disease. The median treatment duration was 6.4 months (95% CI, 4.4–8.4), and the median OS was not reached. In conclusion, NGS tumor profiling was successfully implemented in real-world clinical practice. This enabled the use of molecular profiling-guided therapy which improved survival outcome of selected patients. |
| format | Article |
| id | doaj-art-05180c3b40084053816e79360abd32c7 |
| institution | Kabale University |
| issn | 2045-2322 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj-art-05180c3b40084053816e79360abd32c72025-01-19T12:24:22ZengNature PortfolioScientific Reports2045-23222025-01-0115111410.1038/s41598-024-84909-9Clinical implementation of next-generation sequencing testing and genomically-matched therapy: a real-world data in a tertiary hospitalJin Won Kim0Hee Young Na1Sejoon Lee2Ji-Won Kim3Koung Jin Suh4Se Hyun Kim5Yu Jung Kim6Keun-Wook Lee7Jong Seok Lee8Jaihwan Kim9Jin-Hyeok Hwang10Kihwan Hwang11Chae-Yong Kim12Yong Beom Kim13Soomin Ahn14Kyu Sang Lee15Hyojin Kim16Hye Seung Lee17So Yeon Park18Gheeyoung Choe19Jee Hyun Kim20Jin-Haeng Chung21Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of MedicineDepartment of Pathology, Seoul National University Bundang Hospital, Seoul National University College of MedicineBiomedical Research Institute, Seoul National University Bundang Hospital, Seoul National University College of MedicineDivision of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of MedicineDivision of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of MedicineDivision of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of MedicineDivision of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of MedicineDivision of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of MedicineDivision of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of MedicineDivision of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of MedicineDivision of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of MedicineDepartment of Neurosurgery, Seoul National University Bundang Hospital, Seoul National University College of MedicineDepartment of Neurosurgery, Seoul National University Bundang Hospital, Seoul National University College of MedicineDepartment of Obstetrics and Gynecology, Seoul National University Bundang Hospital, Seoul National University College of MedicineDepartment of Pathology, Seoul National University Bundang Hospital, Seoul National University College of MedicineDepartment of Pathology, Seoul National University Bundang Hospital, Seoul National University College of MedicineDepartment of Pathology, Seoul National University Bundang Hospital, Seoul National University College of MedicineDepartment of Pathology, Seoul National University Bundang Hospital, Seoul National University College of MedicineDepartment of Pathology, Seoul National University Bundang Hospital, Seoul National University College of MedicineDepartment of Pathology, Seoul National University Bundang Hospital, Seoul National University College of MedicineDivision of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of MedicineDepartment of Pathology, Seoul National University Bundang Hospital, Seoul National University College of MedicineAbstract Next-generation sequencing (NGS) cancer profiling has gained traction in routine clinical practice in South Korea. Here, we evaluated the use of NGS testing and genomically-matched therapies for patients with advanced solid tumors in a real-world clinical practice. We analyzed results from NGS cancer panel tests (SNUBH pan-cancer version 2) ordered from June 2019 to June 2020. Genomically-matched treatment was determined based on the novel information obtained from NGS testing, while results from conventional molecular tests were excluded. A total of 990 patients were included in the analysis (median age: 62, Stage IV: 82.5%). Using the Association for Molecular Pathology genetic variant classification system, we found that 257 (26.0%) patients harbored tier I variants, and 859 (86.8%) patients carried tier II variants. Among the tier I cases, the most frequently altered genes we detected were KRAS (106 patients, 10.7%), followed by EGFR (27 patients, 2.7%) and BRAF (17 patients, 1.7%). Of patients with tier I variants, 13.7% received NGS-based therapy as follows: Thyroid cancer (2/7, 28.6%), skin cancer (2/8, 25.0%), gynecologic cancer (7/65, 10.8%), and lung cancer (12/112, 10.7%). Of 32 patients with measurable lesions who received NGS-based therapy, 12 (37.5%) achieved a partial response, and 11 (34.4%) achieved stable disease. The median treatment duration was 6.4 months (95% CI, 4.4–8.4), and the median OS was not reached. In conclusion, NGS tumor profiling was successfully implemented in real-world clinical practice. This enabled the use of molecular profiling-guided therapy which improved survival outcome of selected patients.https://doi.org/10.1038/s41598-024-84909-9 |
| spellingShingle | Jin Won Kim Hee Young Na Sejoon Lee Ji-Won Kim Koung Jin Suh Se Hyun Kim Yu Jung Kim Keun-Wook Lee Jong Seok Lee Jaihwan Kim Jin-Hyeok Hwang Kihwan Hwang Chae-Yong Kim Yong Beom Kim Soomin Ahn Kyu Sang Lee Hyojin Kim Hye Seung Lee So Yeon Park Gheeyoung Choe Jee Hyun Kim Jin-Haeng Chung Clinical implementation of next-generation sequencing testing and genomically-matched therapy: a real-world data in a tertiary hospital Scientific Reports |
| title | Clinical implementation of next-generation sequencing testing and genomically-matched therapy: a real-world data in a tertiary hospital |
| title_full | Clinical implementation of next-generation sequencing testing and genomically-matched therapy: a real-world data in a tertiary hospital |
| title_fullStr | Clinical implementation of next-generation sequencing testing and genomically-matched therapy: a real-world data in a tertiary hospital |
| title_full_unstemmed | Clinical implementation of next-generation sequencing testing and genomically-matched therapy: a real-world data in a tertiary hospital |
| title_short | Clinical implementation of next-generation sequencing testing and genomically-matched therapy: a real-world data in a tertiary hospital |
| title_sort | clinical implementation of next generation sequencing testing and genomically matched therapy a real world data in a tertiary hospital |
| url | https://doi.org/10.1038/s41598-024-84909-9 |
| work_keys_str_mv | AT jinwonkim clinicalimplementationofnextgenerationsequencingtestingandgenomicallymatchedtherapyarealworlddatainatertiaryhospital AT heeyoungna clinicalimplementationofnextgenerationsequencingtestingandgenomicallymatchedtherapyarealworlddatainatertiaryhospital AT sejoonlee clinicalimplementationofnextgenerationsequencingtestingandgenomicallymatchedtherapyarealworlddatainatertiaryhospital AT jiwonkim clinicalimplementationofnextgenerationsequencingtestingandgenomicallymatchedtherapyarealworlddatainatertiaryhospital AT koungjinsuh clinicalimplementationofnextgenerationsequencingtestingandgenomicallymatchedtherapyarealworlddatainatertiaryhospital AT sehyunkim clinicalimplementationofnextgenerationsequencingtestingandgenomicallymatchedtherapyarealworlddatainatertiaryhospital AT yujungkim clinicalimplementationofnextgenerationsequencingtestingandgenomicallymatchedtherapyarealworlddatainatertiaryhospital AT keunwooklee clinicalimplementationofnextgenerationsequencingtestingandgenomicallymatchedtherapyarealworlddatainatertiaryhospital AT jongseoklee clinicalimplementationofnextgenerationsequencingtestingandgenomicallymatchedtherapyarealworlddatainatertiaryhospital AT jaihwankim clinicalimplementationofnextgenerationsequencingtestingandgenomicallymatchedtherapyarealworlddatainatertiaryhospital AT jinhyeokhwang clinicalimplementationofnextgenerationsequencingtestingandgenomicallymatchedtherapyarealworlddatainatertiaryhospital AT kihwanhwang clinicalimplementationofnextgenerationsequencingtestingandgenomicallymatchedtherapyarealworlddatainatertiaryhospital AT chaeyongkim clinicalimplementationofnextgenerationsequencingtestingandgenomicallymatchedtherapyarealworlddatainatertiaryhospital AT yongbeomkim clinicalimplementationofnextgenerationsequencingtestingandgenomicallymatchedtherapyarealworlddatainatertiaryhospital AT soominahn clinicalimplementationofnextgenerationsequencingtestingandgenomicallymatchedtherapyarealworlddatainatertiaryhospital AT kyusanglee clinicalimplementationofnextgenerationsequencingtestingandgenomicallymatchedtherapyarealworlddatainatertiaryhospital AT hyojinkim clinicalimplementationofnextgenerationsequencingtestingandgenomicallymatchedtherapyarealworlddatainatertiaryhospital AT hyeseunglee clinicalimplementationofnextgenerationsequencingtestingandgenomicallymatchedtherapyarealworlddatainatertiaryhospital AT soyeonpark clinicalimplementationofnextgenerationsequencingtestingandgenomicallymatchedtherapyarealworlddatainatertiaryhospital AT gheeyoungchoe clinicalimplementationofnextgenerationsequencingtestingandgenomicallymatchedtherapyarealworlddatainatertiaryhospital AT jeehyunkim clinicalimplementationofnextgenerationsequencingtestingandgenomicallymatchedtherapyarealworlddatainatertiaryhospital AT jinhaengchung clinicalimplementationofnextgenerationsequencingtestingandgenomicallymatchedtherapyarealworlddatainatertiaryhospital |